[1]Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989, 244(4902): 359–362. <\p>

[2]Kang SM, Choi SH, Park CY, Kim MH, Kim TK, Park JM, Koh MS, Kang HJ, Hwang SB. Monoclonal antibody rec-ognizing N-terminal epitope of hepatitis C virus non-structural 5B inhibits viral RNA replication. J Viral Hepat, 2008, 15(4): 305–313. <\p>

[3]Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology, 2004, 39(1): 5–19.<\p>

[4]Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M, Iliopoulos. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular on cogenesis. Cell, 2011, 147(6): 1233–1247.<\p>

[5]Easton DF, Pooley KA, Dunning AM. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007, 447(7148): 1087–1093.<\p>

[6]Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lawlor DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJ, Barroso I, Wareham NJ, Karpe F, Owen KR, Cardon LR, Walker M, Hitman GA, Palmer CN, Doney AS, Morris AD, Smith GD, Hattersley AT, McCarthy MI. A common variant in the FTO gene is associated with body mass index and predis-poses to childhood and adult obesity. Science, 2007, 316(5826): 889–894.<\p>

[7]Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jack-son AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu TL, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Sara-mies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science, 2007, 316(5829): 1341–1345.<\p>

[8]Kanda T, Wu S, Kiyohara T, Nakamoto S, Jiang X, Miya-mura T, Imazeki F, Ishii K, Wakita T, Yokosuka O. Inter-leukin-29 suppresses hepatitis A and C viral internal ribo-somal entry site-mediated translation. Viral Immunol, 2012, 25(5): 379–386.<\p>

[9]Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol, 2003, 4(1): 69–77.<\p>

[10]Sheppard P, Kindsvogel W, Xu WF, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Pres-nell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cy-tokine receptor IL-28R. Nat Immunol, 2003, 4(1): 63–68.<\p>

[11]Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. A variant upstream of IFNL3 (IL28B) creat-ing a new interferon gene IFNL4 is associated with im-paired clearance of hepatitis C virus. Nat Genet, 2013, 45(2): 164–171.<\p>

[12]Pestka S, Krause CD, Walter MR. Interferons, inter-feron-like cytokines, and their receptors. Immunol Rev, 2004, 202(1): 8–32.<\p>

[13]Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-l is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem, 2009, 284(31): 20869–20875.<\p>

[14]McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Gal-ler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Muk-hopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med, 2009, 361(6): 580–593.<\p>

[15]Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med, 2004, 350(22): 2265–2271.<\p>

[16]Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009, 461(7262): 399–401.<\p>

[17]Shi XD, Pan Y, Wang ML, Wang DS, Li WY, Jiang T, Zhang P, Chi XM, Jiang YF, Gao YH, Zhong J, Sun B, Xu DM, Jiang J, Niu JQ. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS ONE, 2012, 7(5): e37054.<\p>

[18]Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is asso-ciated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet, 2009, 41(10): 1100– 1104.<\p>

[19]Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sa-kaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide asso-ciation of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet, 2009, 41(10): 1105–1109.<\p>

[20]Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Mo-radpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 2010, 138(4): 1338–1345.e7.<\p>

[21]Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, Aguilar-Reina J, Núñez- Roldan A, González-Escribano MF. Interleukin-28B ge-netic variants and hepatitis virus infection by different vi-ral genotypes. Hepatology, 2010, 52(1): 33–37.<\p>

[22]Mangia A, Thompson AJ, Santoro R, Piazzolla V, Till-mann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology, 2010, 139(3): 821–827.e1.<\p>

[23]McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, Muir AJ, McHutchison JG. Repli-cated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology, 2010, 138(7): 2307–2314.<\p>

[24]Rembeck K, Alsioa, Christensen PB, Farkkila M, Lange-land N, Buhl MR, Pedersen C, Morch K, Westin J, Lindh M, Hellstrand K, Norkrans G, Lagging M. Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS ONE, 2012, 7(1): e29370.<\p>

[25]Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, Shianna KV, Vispo E, Thompson A, McHutchison J, Soriano V. Association of a single nucleo-tide polymorphism near the interleukin-28B gene with re-sponse to hepatitis C therapy in HIV/hepatitis C vi-rus-coinfected patients. AIDS, 2010, 24(8): F23–F29.<\p>

[26]Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Fer-enci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telapre-vir for previously untreated chronic hepatitis C virus in-fection. N Engl J Med, 2011, 364(25): 2405–2416.<\p>

[27]Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med, 2011, 364(13): 1195–1206.<\p>

[28]Thomas DL, Thio CL, Martin MP, Qi Y, Ge DL, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 2009, 461(7265): 798–801.<\p>

[29]Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grungreiff K, König I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J. A polymor-phism near IL28B is associated with spontaneous clear-ance of acute hepatitis C virus and jaundice. Gastroen-terology, 2010, 139(5): 1586–1592.e1.<\p>

[30]Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Brau N, Hatzakis A, Pol S, Rock-stroh J. Care of patients co-infected with HIV and hepati-tis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS, 2007, 21(9): 1073– 1089.<\p>

[31]Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology, 2010, 139(6): 1865–1876.<\p>

[32]Lunge VR, da Rocha DB, Beria JU, Tietzmann DC, Stein AT, Simon D. IL28B polymorphism associated with spon-taneous clearance of hepatitis C infection in a Southern Brazilian HIV type 1 population. AIDS Res Hum Retrovi-ruses, 2012, 28(2): 215–219.<\p>

[33]Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, Buchbinder S, Carrington M, Thio CL. IL28B poly-morphism does not determine outcomes of hepatitis B vi-rus or HIV infection. J Infect Dis, 2010, 202(11): 1749– 1753.<\p>

[34]Kim SU, Song KJ, Chang HY, Shin EC, Park JY, Kim do Y, Han KH, Chon CY, Ahn SH. Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection. PLoS ONE, 2013, 8(7): e69166.<\p>

[35]Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, Dev A, Bell S, Pianko S, Chen R, Vis-vanathan K, Hammond R, Iser D, Rusli F, Sievert W, Desmond PV, Bowden DS, Thompson AJ. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated inter-feron-α. J Gastroenterol Hepatol, 2013, 28(5): 861–866.<\p>

[36]Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, Nattermann J, Oldenburg J, Sauerbruch T, Spengler U. Interferon-lambda serum levels in hepatitis C. J Hepatol, 2011, 54(5): 859–865.<\p>

[37]Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S. Hepatic ISG ex-pression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology, 2010, 139(2): 499–509.<\p>

[38]Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-a regulates TLR-dependent gene expression of IFN-a, IFN-b, IL-28, and IL-29. J Immunol, 2005, 174(4): 1932–1937.<\p>

[39]Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, Cella M, Lande R, Uze G. Viral infection and Toll-like receptor agonists induce a differential ex-pression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol, 2004, 34(3): 796–805.<\p>

[40]Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of IFN-l in murine tumor models. J Immunol, 2006, 176(12): 7686–7694.<\p>

[41]Mennechet FJD, Uze G. Interferon-l-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood, 2006, 107(11): 4417–4423.<\p>

[42]Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV. Regulation of apoptosis by type III interferons. Cell Prolif, 2008, 41(6): 960–979.<\p>

[43]Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev, 2002, 13(3): 223–240.<\p>

[44]Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K. Despite IFN-λ receptor ex-pression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III inter-ferons: implications for therapeutic applications of these cytokines target cells of type III interferons. Genes Immun, 2009, 10(8): 702–714.<\p>

[45]Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Ko-tenko SV, Renauld JC. Role of the interleukin (IL)-28 re-ceptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-λ1: similarities with type I in-terferon signaling. J Biol Chem, 2004, 279(31): 32269– 32274.<\p>

[46]Zhang LL, Jilg N, Shao RX, Lin WY, Fusco DN, Zhao H, Goto K, Peng LF, Chen WC, Chung RT. IL28B inhibits hepatitis C virus replication through the JAK-STAT path-way. J Hepatol, 2011, 55(2): 289–298.<\p>

[47]Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine, 2005, 31(2): 109–118.<\p>

[48]Cheng M, Si YH, Yang Y, Liu XY, Gong QL, Zhao J, Niu YQ, Li X, Jin Q, Yang W. Recombinant human interleukin 28B: anti -HCV potency, receptor usage and restricted cell-type responsiveness. J Antimicrob Chemother, 2012, 67(5): 1080–1087.<\p>

[49]Renauld JC. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Im-munol, 2003, 3(8): 667–676.<\p>

[50]Zitzmann K, Brand S, Baehs S, Goke B, Meinecke J, Spottl G, Meyer H, Auernhammer CJ. Novel interferon-ls induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun, 2006, 344(4): 1334– 1341.<\p>

[51]Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-l), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol, 2006, 80(9): 4501–4509.<\p>

[52]Li QH, Kawamura K, Ma GY, Iwata F, Numasaki M, Su-zuki N, Shimada H, Tagawa M. Interferon-l induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer, 2010, 46(1): 180–190.